Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient
Primary Purpose
Gastric Cancer, Obesity
Status
Completed
Phase
Phase 3
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Sugammadex Sodium
Sponsored by
About this trial
This is an interventional treatment trial for Gastric Cancer
Eligibility Criteria
Inclusion Criteria:
- Gastric cancer patients with laparoscopic subtotal gastrectomy
- 19-75 years
- Body mass index(BMI) > 25kg/m2
- American Society of Anesthesiologists I-III
Exclusion Criteria:
- American Society of Anesthesiologists Class IV
- End stage renal disease (ESRD) patient
- Patients with allergy to muscle relaxants
- Patients with diseases that may affect muscle relaxation
Sites / Locations
- Korea University Anam Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Deep neuromuscular block group
Moderate neuromuscular group
Arm Description
Sugammadex sodium 4mg/kg/IV after operation
Sugammadex sodium 2mg/kg/IV after operation
Outcomes
Primary Outcome Measures
Number of Retrieved Lymph Nodes Per Participant
Number of retrieved lymph nodes per participant, which was reported on final pathology report, after completing the laparoscopic surgery
Secondary Outcome Measures
Surgical Rating Score (SRS)
Surgical rating score (SRS) at Four anatomical area during LN dissection
During surgery, the surgeon reported the SRS based on the Leiden surgical rating scale (1=extremely poor, 2=poor, 3=acceptable, 4=good, 5=optimal) for each anatomical landmark (LN stations 4sb, 6, and 5 and the suprapancreatic area).
Number of Participants With at Least One Interruption Event
Interrupted event by patient movement, coughing, muscle spasm during operation
Intraoperative Blood Loss Amount
Amount of bleeding during operation
Full Information
NCT ID
NCT03196791
First Posted
June 20, 2017
Last Updated
June 20, 2021
Sponsor
Korea University Anam Hospital
1. Study Identification
Unique Protocol Identification Number
NCT03196791
Brief Title
Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient
Official Title
A Double-blind, Randomized and Controlled Multicenter Prospective Trial to Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient
Study Type
Interventional
2. Study Status
Record Verification Date
June 2021
Overall Recruitment Status
Completed
Study Start Date
October 10, 2017 (Actual)
Primary Completion Date
August 9, 2020 (Actual)
Study Completion Date
September 9, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Korea University Anam Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study is designed to evaluate the impact of muscle relaxation during laparoscopic gastrectomy on oncological benefit, especially with obese patients over BMI 25. The primary endpoint is number of harvested lymph node that is critical point regarding quality of surgery in gastric cancer treatment. The secondary endpoint is intraoperative bleeding, surgeons' satisfaction.
The patients were randomly assigned to two groups using a computer-generated randomization table : 196 persons
Deep neuromuscular block group (98persons)
Moderate neuromuscular group (98persons)
Detailed Description
This study is designed to evaluate the impact of muscle relaxation during laparoscopic gastrectomy on oncological benefit, especially with obese patients over BMI 25. This is a randomized controlled trial comparing deep NMB with moderate NMB in laparoscopic subtotal gastrectomy in obese patients with gastric cancer. The design of the study is blinded (the surgical team and the research team are all blinded to the treatment); the attending anesthesiologist is not blinded. The primary endpoint is number of harvested lymph node that is critical point regarding quality of surgery in gastric cancer treatment. The secondary endpoint is intraoperative bleeding, surgeons' satisfaction.
The patients were randomly assigned to two groups using a computer-generated randomization table : 196 persons
Deep neuromuscular block group (98persons)
Moderate neuromuscular group (98persons) The patients are assigned to the deep NMB group or the moderate NMB group. The clinical research coordinator (CRC) uses a computer randomization program to determine the degree of muscle relaxation of each patient. Stratified block randomization is used to guarantee even distribution, which means that all participating hospitals are assigned moderate or deep NMB randomly in a 1:1 ratio. The CRC notifies the anesthesiologist of the degree of muscle relaxation just before the operation. Surgeons are blinded to the degree of muscle relaxation: They can enter the operating room after the muscle relaxation has been performed. A train-of-four (TOF) monitor is placed out of the surgeon's visual field. The anesthesiologist injects sugammadex after confirming the absence of the surgeon. The ward staff members who evaluate patient outcomes are blinded to the degree of muscle relaxation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastric Cancer, Obesity
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
196 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Deep neuromuscular block group
Arm Type
Experimental
Arm Description
Sugammadex sodium 4mg/kg/IV after operation
Arm Title
Moderate neuromuscular group
Arm Type
Experimental
Arm Description
Sugammadex sodium 2mg/kg/IV after operation
Intervention Type
Drug
Intervention Name(s)
Sugammadex Sodium
Other Intervention Name(s)
Bridion®, MSD
Intervention Description
INDICATIONS AND USAGE BRIDION® is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. BRIDION (sugammadex) injection is a sterile, clear, colorless to slightly yellow-brown, non-pyrogenic aqueous solution intended for intravenous infusion.
DOSAGE AND ADMINISTRATION BRIDION (sugammadex) injection, for intravenous use, should be administered by trained healthcare providers familiar with the use, actions, characteristics, and complications of neuromuscular blocking agents (NMBA) and neuromuscular block reversal agents.
Primary Outcome Measure Information:
Title
Number of Retrieved Lymph Nodes Per Participant
Description
Number of retrieved lymph nodes per participant, which was reported on final pathology report, after completing the laparoscopic surgery
Time Frame
within 14 days after operation
Secondary Outcome Measure Information:
Title
Surgical Rating Score (SRS)
Description
Surgical rating score (SRS) at Four anatomical area during LN dissection
During surgery, the surgeon reported the SRS based on the Leiden surgical rating scale (1=extremely poor, 2=poor, 3=acceptable, 4=good, 5=optimal) for each anatomical landmark (LN stations 4sb, 6, and 5 and the suprapancreatic area).
Time Frame
immediately after the operation
Title
Number of Participants With at Least One Interruption Event
Description
Interrupted event by patient movement, coughing, muscle spasm during operation
Time Frame
immediately after surgery
Title
Intraoperative Blood Loss Amount
Description
Amount of bleeding during operation
Time Frame
immediately after the operation
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Gastric cancer patients with laparoscopic subtotal gastrectomy
19-75 years
Body mass index(BMI) > 25kg/m2
American Society of Anesthesiologists I-III
Exclusion Criteria:
American Society of Anesthesiologists Class IV
End stage renal disease (ESRD) patient
Patients with allergy to muscle relaxants
Patients with diseases that may affect muscle relaxation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sung soo Park, MD,PhD
Organizational Affiliation
Korea University Anam Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Korea University Anam Hospital
City
Seoul
ZIP/Postal Code
02841
Country
Korea, Republic of
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
35213496
Citation
Park SH, Huh H, Choi SI, Kim JH, Jang YJ, Park JM, Kwon OK, Jung MR, Jeong O, Lee CM, Min JS, Kim JJ, An L, Yang KS, Park S, Lee IO; Deep Neuromuscular Block on Oncologic Quality of Laparoscopic Surgery in Obese Gastric Cancer Patients (DEBLOQS_GC) Study Group. Impact of the Deep Neuromuscular Block on Oncologic Quality of Laparoscopic Surgery in Obese Gastric Cancer Patients: A Randomized Clinical Trial. J Am Coll Surg. 2022 Mar 1;234(3):326-339. doi: 10.1097/XCS.0000000000000061.
Results Reference
derived
PubMed Identifier
30544421
Citation
Lee Y, Ha D, An L, Jang YJ, Huh H, Lee CM, Kim YH, Kim JH, Park SH, Mok YJ, Lee IO, Kwon OK, Kwak KH, Min JS, Kim EJ, Choi SI, Yi JW, Jeong O, Jung MR, Bae HB, Park JM, Jung YH, Kim JJ, Kim DA, Park S. Comparison of oncological benefits of deep neuromuscular block in obese patients with gastric cancer (DEBLOQS_GC study): A study protocol for a double-blind, randomized controlled trial. Medicine (Baltimore). 2018 Dec;97(49):e13424. doi: 10.1097/MD.0000000000013424. Erratum In: Medicine (Baltimore). 2019 Jan;98(1):e14141.
Results Reference
derived
Learn more about this trial
Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient
We'll reach out to this number within 24 hrs